Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(5.08) per share which missed the analyst consensus estimate of $(2.16) by 135.62 percent. This is a 3.25 percent decrease over losses of $(4.92) per share from the same period last year. The company reported quarterly sales of $287.268 million which beat the analyst consensus estimate of $245.386 million by 17.07 percent. This is a 362.03 percent increase over sales of $62.175 million the same period last year.